Work

PTCY keeps on giving!

Year: 2019

Type: article

Abstract: In this issue of Blood, Battipaglia and colleagues report improved outcomes for patients receiving posttransplant cyclophosphamide (PTCY) vs antithymocyte globulin (ATG) as backbone of their immunosuppression regimen after 1-antigen mismatched unrelated donor (MMUD) allogeneic hematopoietic cell transplantation (alloHCT) for treatment of acute myeloid leukemia (AML). 1

Source: Blood

DOI: 10.1182/blood.2019002284

Authors: Vedran Radojcic, Leo Luznik

Institutions: University of Utah, Huntsman Cancer Institute, Sidney Kimmel Comprehensive Cancer Center

Language: English

Topic: Hematopoietic Stem Cell Transplantation

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: green

Funders: Genentech, National Heart, Lung, and Blood Institute